Provided by Tiger Trade Technology Pte. Ltd.

Palisade Bio Inc.

2.00
+0.04002.04%
Post-market: 1.95-0.0488-2.44%19:32 EDT
Volume:3.53M
Turnover:6.92M
Market Cap:331.77M
PE:-6.63
High:2.00
Open:1.94
Low:1.93
Close:1.96
52wk High:2.64
52wk Low:0.5300
Shares:165.88M
Float Shares:122.00M
Volume Ratio:1.06
T/O Rate:2.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3014
EPS(LYR):-0.3014
ROE:-24.52%
ROA:-15.54%
PB:2.56
PE(LYR):-6.63

Loading ...

Palisade Bio Down Over 15%, on Pace for Largest Percent Decrease Since December 2024 -- Data Talk

Dow Jones
·
Jan 06

Palisade Bio Initiated at Buy by Clear Street

Dow Jones
·
Dec 31, 2025

Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

GlobeNewswire
·
Dec 30, 2025

Palisade Bio Initiated at Overweight by Piper Sandler

Dow Jones
·
Dec 29, 2025

U.S. RESEARCH ROUNDUP-Expedia Group, Hasbro, Palisade Bio

Reuters
·
Dec 29, 2025

Palisade Bio Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $25

THOMSON REUTERS
·
Dec 29, 2025

BRIEF-Palisade Bio Strengthens Clinical Leadership Team With Appointment Of James Izanec

Reuters
·
Dec 02, 2025

Palisade Bio Strengthens Clinical Leadership Team With Appointment of James Izanec, Md, Agaf as Vice President, Clinical Development

THOMSON REUTERS
·
Dec 02, 2025

Palisade Bio price target raised to $8 from $2 at Maxim

TIPRANKS
·
Nov 12, 2025

Palisade Bio Inc expected to post a loss of 27 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Palisade Bio Inc. Announces Date for Upcoming Special Stockholders Meeting

Reuters
·
Oct 29, 2025

BRIEF-Palisade Bio Appoints Sharon Skare As Vice President, Global Head Of Clinical Operations

Reuters
·
Oct 28, 2025

Palisade Bio Inc. held annual shareholder meeting

Reuters
·
Oct 21, 2025

Palisade Bio Inc. Announces Date for Upcoming Special Stockholders Meeting

Reuters
·
Oct 20, 2025

BRIEF-Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

Reuters
·
Oct 20, 2025

Palisade Bio Inc - Data to Support Phase 2 Ind Submissions to FDA in H1 2026

THOMSON REUTERS
·
Oct 20, 2025

Palisade Bio Inc - Topline Data for Pali-2108 Study Expected in Q1 2026

THOMSON REUTERS
·
Oct 20, 2025

Palisade Bio Announces First Patients Dosed in Phase 1B Study of Oral First-in-Class Pde4 Inhibitor Prodrug, Pali-2108, for the Treatment of Fibrostenotic Crohn’s Disease (Fscd)

THOMSON REUTERS
·
Oct 20, 2025

Palisade Bio granted Canadian patent covering PALI-2108 composition

TIPRANKS
·
Oct 13, 2025

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

GlobeNewswire
·
Oct 13, 2025